Fate Therapeutics FT839 CAR T Shows Strong Preclinical Data
SAN DIEGO, Calif., April 16, 2026 Fate Therapeutics, Inc. has announced the presentation of preclinical data for its next-generation...
Autoimmune Disease
Advertisement
Resolve and Pasteur Advance cfRNA Autoimmune Research
MONTEVIDEO, Uruguay & NEW YORK, United States, April 7, 2026 Resolve Therapeutics and the Institut Pasteur de Montevideo announced...
Fortitude Advances T-Cell Therapy for Axial Disease
WALTHAM, Massachusetts, United States, April 7, 2026 Fortitude Biomedicines, Inc. announced progress on its lead immunology program, a first-in-class...
Amgen TEPEZZA Subcutaneous Trial Shows Strong Phase 3 Results
Thousand Oaks, California, USA, April 6, 2026 Phase 3 Success Expands TEPEZZA Treatment Options In a major advancement for...
Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
Advertisements
FDA Grants Fast Track to Nipocalimab for Lupus Treatment
SPRING HOUSE, Pa., March 3, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) Fast Track...
J&J Files FDA Application for IMAAVY in wAIHA
February 24, 2026 – Spring House, Pennsylvania, USA Johnson & Johnson has announced the submission of a supplemental Biologics...
Parse and Graph Launch Massive AI-Driven Immune Atlas
Seattle and Vienna, January 20, 2026 — Parse Biosciences and Graph Therapeutics have announced a strategic partnership to create...
Legacy Advances Cinainu into Phase 3 Alopecia Areata Trial
LAUSANNE, Switzerland | January 6, 2026 — Legacy Healthcare announced that it will advance its topical botanical drug candidate,...
PeptiDream Advances Oral IL-17 Therapy for Psoriasis
KANAGAWA, Japan, Dec. 17, 2025 — PeptiDream Inc. announced promising pre-clinical results for a novel oral dual IL-17A and...
Advertisement
